Susan Galbraith

Stories

FDA panel weighs blood-test-guided early drug switch for breast cancer

Defending the camizestrant filing before ODAC

For decades, oncologists changed breast cancer drugs only after a scan showed the tumor growing back. On April 30, 2026, an FDA advisory panel weighed a different approach: switch the drug the moment a blood test detects the resistance mutation — weeks or months before the cancer becomes visible on imaging.

Updated May 31

FDA approves Enhertu for early-stage HER2-positive breast cancer

New Capabilities

Leading AstraZeneca's oncology pipeline; Enhertu is the company's top-selling cancer drug

The U.S. Food and Drug Administration (FDA) cleared AstraZeneca and Daiichi Sankyo's Enhertu for two new uses in early-stage HER2-positive breast cancer in May 2026. The drug, already a standard for advanced disease, now enters the window where the goal is cure, not control.

Updated May 18